Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 184

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 184
---
decision maker (“CODM”) assesses the performance of and allocates resources. The CODM is the Chief Executive Officer. Diagnostic
R&D includes research and development and clinical development on diagnostic tests. Any revenues assigned to Diagnostic R&D are
proceeds received from observational studies. Laboratory services include all the operations from Village Oaks and PPLS in addition to
sales and marketing costs of CyPathLung from bioAffinity Technologies.

SCHEDULE OF SEGMENT INFORMATION

| Net revenues:                       |     | 2025            
 As of March 31, 
 2025            |            |   |     | 2024 
 2024 |            |   |
|:------------------------------------|:----|:----------------|-----------:|:--|:----|:-----|-----------:|:--|
| Diagnostic R&D                      |     | $               |          — |   |     | $    |      2,885 |   |
| Laboratory services                 |     |                 |  1,853,597 |   |     |      |  2,403,506 |   |
| Total net revenues                  |     |                 |  1,853,597 |   |     |      |  2,406,391 |   |
| Operating expenses:                 |     |                 |            |   |     |      |            |   |
| Diagnostic R&D                      |     |                 |   (505,739 | ) |     |      |   (442,599 | ) |
| Laboratory services                 |     |                 | (2,267,656 | ) |     |      | (2,736,999 | ) |
| General corporate activities        |     |                 | (1,707,341 | ) |     |      | (1,172,023 | ) |
| Total operating loss                |     |                 | (2,627,139 | ) |     |      | (1,945,230 | ) |
| Non-operating income (expense), net |     |                 |    (24,583 | ) |     |      |    (12,913 | ) |
| Net loss before income taxes        |     |                 | (2,651,722 | ) |     |      | (1,958,143 | ) |
| Income tax expense                  |     |                 |     (8,695 | ) |     |      |     (3,672 | ) |
| Net loss